Health Condition 1: null- Colorectal cancer Health Condition 2: C189- Malignant neoplasm of colon, unspecified
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: patients above age of 18 yrs Planned for Capecitabine based chemotherapy for colorectal cancer in adjuvant or metastatic setting Can either read or write English, or Hindi or Marathi. Creatinine clearance > 60 ml/min Receiving capectabine in dose of 2000mg/m2/day
Exclusion criteria
Exclusion criteria: Patients who are not willing to participate in the study patients with previous history of hand foot syndrome Previous exposure to 5-FU or Capecitabine Chemotherapy regimens which increase capecitabine induced toxicities e.g. irinotecan induced diarrhea requiring dose reduction of both Capecitabine and irinotecan. LFTs : AST/ALT > 3 ULN, bilirubin > 1.5 ULN, Albumin
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To evaluate in a multivariate analysis the effect of several pre-treatment factors on the occurrence of grade 3 or worse diarrhoea. The factors will be treatment arm, BMI, gender, Age, Albumin, and haemoglobinTimepoint: 2 year | — |
Primary
| Measure | Time frame |
|---|---|
| To study the effect of Structured Teaching module (STM) on incidence and severity of Hand Foot syndrome among patients receiving Capecitabine based chemotherapy for colorectal cancer at a Tertiary Cancer Care CentreTimepoint: 2 year | — |
Countries
India
Contacts
Tata Memorial Hospital